The presence of CD20+CD22+ADAM28+ B cells in the TLSs was verified in multiple types of cancers, including colorectal cancer (CRC), breast cancer, skin squamous cell cancer (SCC), and renal clear cell cancer (RCC) (Figures 6D, S7D). This evidence concerns the gene CD22 and colorectal carcinoma.